Asia On The Move: Novo Appoints New China GM
This article was originally published in PharmAsia News
Novo Nordisk has promoted a VP from Southeast Asia to lead its China operations, amid a flurry of key executive changes at multinational drug makers in China. Top executive changes are also taking place at Abbvie, Nippon Kayaku and UCB in Japan.
You may also be interested in...
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.